Article

Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years

2022-03-28

Abstract excerpt

Background<br>Since it was first identified in early November 2021, the coronavirus disease 2019 (Covid-19) B.1.1.529 (omicron) variant has spread quickly and replaced the B.1.617.2 (delta) variant as the dominant variant in many countries. Data on the real-world effectiveness of vaccines against the omicron variant for children is currently lacking.<br><br>Methods<br>We performed a study of 255,773 children betwe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b3d5863d-c9d7-5cb0-bea2-59638ce47186
DOI: 10.2139/ssrn.4052133

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 YearsDOI 10.2139/ssrn.4052133Read

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron VariantSemantic proximity Read

Real-world Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and AdolescentsSemantic proximity Read

Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in ArgentinaSemantic proximity Read

Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 Vaccines Against Hospitalisations Among Children and Adolescents During the Omicron Outbreak in ArgentinaSemantic proximity Read

Effectiveness of BNT162b2 COVID-19 Vaccination in Children Aged 5–17 Years in the United StatesSemantic proximity Read

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concernSemantic proximity Read

The BTN162b2 Vaccine Induces Humoral and Cellular Immune Memory to Wuhan Strain SARS-CoV-2 and the Omicron Variant in Children 5 to 11 Years of AgeSemantic proximity Read

Effectiveness of BNT162b2 and CoronaVac against pediatric COVID-19-associated hospitalization and moderate-to-severe diseaseSemantic proximity Read

Vaccine effectiveness of CoronaVac against symptomatic and severe COVID-19 among children in Brazil during the Omicron periodSemantic proximity Read

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in BrazilSemantic proximity Read

Safety of the BNT162b2 mRNA COVID-19 Vaccine in Children below 5 Years (CoVacU5) – an Investigator-Initiated Retrospective Cohort StudySemantic proximity Read

Vaccine Effectiveness of Two-Dose BNT162b2 Over Time Against COVID-19 Symptomatic Infection and Severe Cases Among Adolescents: Test Negative Design Case Control Studies in Brazil and ScotlandSemantic proximity Read